Ambrosio, Maria Rosaria
Gagliardi, Irene
Chiloiro, Sabrina http://orcid.org/0000-0001-9241-2392
Ferreira, Ana Gonçalves
Bondanelli, Marta http://orcid.org/0000-0001-8071-6559
Giampietro, Antonella http://orcid.org/0000-0001-5756-2045
Bianchi, Antonio http://orcid.org/0000-0002-4896-5499
Marinis, Laura De http://orcid.org/0000-0001-9916-0669
Fleseriu, Maria http://orcid.org/0000-0001-9284-6289
Zatelli, Maria Chiara http://orcid.org/0000-0001-8408-7796
Funding for this research was provided by:
University of Ferrara (FAR2019, FAR2019)
Article History
Received: 25 October 2019
Accepted: 14 January 2020
First Online: 14 February 2020
Compliance with ethical standards
:
: MRA reports registration fees for scientific meetings from Ipsen, Novartis, Pfizer, and Savio Pharma. LDM reports that she has been Principal Investigator for clinical trials for Novartis, Ipsen, Pfizer, and Chiasma. MF has been a principal investigator for studies with research grants to Oregon Health & Science University from Chiasma, Crinetics, Ionis, Novartis, Pfizer and has been an occasional scientific consultant to Chiasma, Crinetics, Ipsen, Novartis, Pfizer. MCZ received consulting fees from Sanofi, Novartis and Ipsen; received financial support for scientific meetings and for research support from Itapharma, Abiogen, Sanofi, Novartis and Ipsen. IG, SC, AGF, MB, AG, AB have no actual or potential conflict of interest in relation to this paper.